Publications
- Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry2020 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University
- Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib2020 | Faculty of Medicine in Pilsen
- Effect of clinical parameters on second- and third-line erlotinib treatment of EGFR wild type patients with advanced NSCLC2019 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University
- Immunotherapy in squamous NSCLC - nivolumab clinical data, our experiences with nivolumab treatment2018 | Faculty of Medicine in Pilsen
- Erlotinib in treatment of NSCLC focusing on patients without EGFR mutation and on combination of erlotinib with bevacizumab2017 | Faculty of Medicine in Pilsen
- Erlotinib in Treatment of NSCLC (Focusing on Patients without EGFR Mutation and on Combination of Erlotinib with Bevacizumab)2017 | Faculty of Medicine in Pilsen
- Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib2016 | Faculty of Medicine in Pilsen, Faculty of Science, First Faculty of Medicine
- Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene2016 | Faculty of Medicine in Pilsen, Faculty of Science
- LUX-LUNG 7 - new look at the first line treatment for patients with frequent EGFR mutations?2016 | Faculty of Medicine in Pilsen
- Tumor Rebiopsy - Guide to Targeted Therapy2016 | Faculty of Medicine in Pilsen
Loading network view...